FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Expires: December 31, 2014 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person * SMITH-VAN VURST ANDREW (Last) (First) (Middle) C/O BIOSTEM TECHNOLOGIES, INC. 2836 CENTER PORT CIRCLE (Street) POMPANO BEACH FL 33064 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol BioStem Technologies, Inc. [ BSEM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) Chief Operating Officer
	3. Date of Earliest Transaction (Month/Day/Year) 10/07/2026
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2026		M		250,000	A	$ 2	1,789,809	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-1 Convertible Preferred Shares	(1)							05/23/2016	(2)	Common Stock	100		100 (3)	D
Options (Right to Buy)	$ 2	10/07/2026		M			250,000	(4)	10/24/2032	Common Stock	250,000	$ 0	2,000,000	D
Options (Right to Buy)	$ 10.05							(5)	03/17/2035	Common Stock	114,314		114,314	D
Options (Right to Buy)	$ 10.05							(6)	10/13/2035	Common Stock	23,246		23,246	D
Options (Right to Buy)	$ 5.5							(7)	02/11/2036	Common Stock	253,304		253,304	D
Restricted Stock Units	(8)							(9)	(9)	Common Stock	30,487		30,487	D
Restricted Stock Units	(8)							(10)	(10)	Common Stock	57,442		57,442	D
Restricted Stock Units	(8)							(11)	(11)	Common Stock	209,091		209,091	D

Explanation of Responses:

1. The Series A-1 Convertible Preferred Shares are convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.

2. The Series A-1 Convertible Preferred Shares have no expiration date.

3. Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.

4. These options are fully vested and exercisable.

5. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

6. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

7. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

8. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

9. These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024).

10. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

11. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

	/s/ Katherine Gorrell, Attorney-in-Fact	10/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.